Finerenone reduces risk of new-onset AF in patients with CKD, T2D
12 Jun 2021
byElaine Soliven
Treatment with finerenone led to a significantly reduced risk of new-onset atrial fibrillation (AF) in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D), according to the FIDELIO-DKD* trial presented at the ACC.21 Virtual Meeting.
Finerenone reduces risk of new-onset AF in patients with CKD, T2D
12 Jun 2021